Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a public health concern worldwide. Ensitrelvir (S-217622) has been evaluated as an antiviral treatment for COVID-19, targeting SARS-CoV-2 3C-like protease (3CL(pro)). Ensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashima, Sho, Matsui, Yuki, Adachi, Takumi, Morikawa, Yuji, Inoue, Kae, Takebayashi, Shiori, Nobori, Haruaki, Rokushima, Masatomo, Tachibana, Yuki, Kato, Teruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839456/
https://www.ncbi.nlm.nih.gov/pubmed/36689809
http://dx.doi.org/10.1016/j.bbrc.2023.01.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839456/
https://www.ncbi.nlm.nih.gov/pubmed/36689809
http://dx.doi.org/10.1016/j.bbrc.2023.01.040

Ejemplares similares